HER2-Negative Metastatic Breast Cancer Market Positioned for Accelerated Development Through 2032, DelveInsight Finds | Genentech, AstraZeneca, Merck Sharp & Dohme LLC, Gilead Sciences, BeiGene, Eisai

The Key HER2-Negative Metastatic Breast Cancer Companies in the market include - Genentech, Inc., AstraZeneca, Merck Sharp & Dohme LLC, Gilead Sciences, BeiGene, Eisai Inc., Novartis Pharmaceuticals, Adagene Inc, Jiangsu HengRui Medicine Co., Ltd, Pfizer, Novartis, CytomX Therapeutics, Tyme, Inc, Puma Biotechnology, Inc., G1 Therapeutics, Inc., Context Therapeutics Inc., and others.

DelveInsight's "HER2-Negative Metastatic Breast Cancer Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the HER2-Negative Metastatic Breast Cancer, historical and forecasted epidemiology as well as the HER2-Negative Metastatic Breast Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the HER2-Negative Metastatic Breast Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; HER2-Negative Metastatic Breast Cancer Market Forecast [https://www.delveinsight.com/sample-request/her2-negative-metastatic-breast-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the HER2-Negative Metastatic Breast Cancer Market Report:

*
The HER2-Negative Metastatic Breast Cancer market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

*
In January 2025, Genentech Therapeutics' Phase III clinical trial of Itovebi achieved the key oncology benchmark of improved overall survival (OS) in patients with certain forms of metastatic breast cancer, while also delaying disease progression. Additional findings from the randomized, double-blind study (NCT04191499) revealed that Itovebi, also known as inavolisib, demonstrated a statistically significant and clinically meaningful improvement in OS when combined with Ibrance (palbociclib) and Faslodex (fulvestrant). This benefit was specifically observed in patients with PIK3CA-mutated, hormone receptor (HR)-positive, and HER2-Negative Metastatic Breast Cancer.

*
In January 2025, Mersana Therapeutics, Inc. announced that the US Food and Drug Administration (FDA) has granted an additional Fast Track designation to XMT-1660. This designation applies to the treatment of advanced or metastatic breast cancer in patients with HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-negative (IHC 0) disease, including triple-negative breast cancer (TNBC), who have previously received a topoisomerase-1 inhibitor ADC.

*
In November 2024, Pyxis Oncology, Inc. reported encouraging preliminary results from its ongoing Phase I dose-escalation study assessing PYX-201 across various solid tumor types.

*
The US experienced 253,465 new instances of breast cancer in 2020, according to the Global Cancer Observatory (2020)

*
According to data from Surveillance, Epidemiology and End Results (SEER, n.d.), the US female population experiences the diagnosis of more than 200,000 new instances of breast cancer each year

*
According to the Global Cancer Observatory (2020), there were 69,697 new cases of breast cancer in Germany, France, Italy, Spain, and the United Kingdom, respectively, in 2020

*
Key HER2-Negative Metastatic Breast Cancer Companies: Genentech, Inc., AstraZeneca, Merck Sharp & Dohme LLC, Gilead Sciences, BeiGene, Eisai Inc., Novartis Pharmaceuticals, Adagene Inc, Jiangsu HengRui Medicine Co., Ltd, Pfizer, Novartis, CytomX Therapeutics, Tyme, Inc, Puma Biotechnology, Inc., G1 Therapeutics, Inc., Context Therapeutics Inc., and others

*
Key HER2-Negative Metastatic Breast Cancer Therapies: Paclitaxel, Doxorubicin, AZD9833, Pembrolizumab, TF2 - 68 Ga-IMP-288, BGB-290, Eribulin, Dapagliflozin, ADG106, Famitinib Malate, Talazoparib Tosylate, Letrozole, CX-2009, SM-88, Neratinib, G1T38, Onapristone, and others

*
The HER2-Negative Metastatic Breast Cancer epidemiology based on gender analyzed that HER2-Negative Metastatic Breast Cancer mainly develops in older women

*
The HER2-Negative Metastatic Breast Cancer market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage HER2-Negative Metastatic Breast Cancer pipeline products will significantly revolutionize the HER2-Negative Metastatic Breast Cancer market dynamics.

HER2-Negative Metastatic Breast Cancer Overview

HER2-Negative Metastatic Breast Cancer is a type of breast cancer that has spread beyond the breast and nearby lymph nodes to other parts of the body (metastatic) and does not overexpress the human epidermal growth factor receptor 2 (HER2) protein. Since HER2 is not overactive, HER2-targeted therapies like trastuzumab are ineffective. Treatment typically focuses on hormonal therapy, chemotherapy, or immunotherapy, depending on hormone receptor status (HR-positive or triple-negative). HER2-negative status influences prognosis and treatment strategy.

Get a Free sample for the HER2-Negative Metastatic Breast Cancer Market Report

https://www.delveinsight.com/report-store/her2-negative-metastatic-breast-cancer-market [https://www.delveinsight.com/report-store/her2-negative-metastatic-breast-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

HER2-Negative Metastatic Breast Cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

HER2-Negative Metastatic Breast Cancer Epidemiology Segmentation:

The HER2-Negative Metastatic Breast Cancer market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:

*
Total Prevalence of HER2-Negative Metastatic Breast Cancer

*
Prevalent Cases of HER2-Negative Metastatic Breast Cancer by severity

*
Gender-specific Prevalence of HER2-Negative Metastatic Breast Cancer

*
Diagnosed Cases of Episodic and Chronic HER2-Negative Metastatic Breast Cancer

Download the report to understand which factors are driving HER2-Negative Metastatic Breast Cancer epidemiology trends @ HER2-Negative Metastatic Breast Cancer Epidemiology Forecast [https://www.delveinsight.com/sample-request/her2-negative-metastatic-breast-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

HER2-Negative Metastatic Breast Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the HER2-Negative Metastatic Breast Cancer market or expected to get launched during the study period. The analysis covers HER2-Negative Metastatic Breast Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the HER2-Negative Metastatic Breast Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

HER2-Negative Metastatic Breast Cancer Therapies and Key Companies

*
Paclitaxel: Dana-Farber Cancer Institute

*
Doxorubicin: Genentech, Inc.

*
AZD9833: AstraZeneca

*
Pembrolizumab: Merck Sharp & Dohme LLC

*
TF2 - 68 Ga-IMP-288: Gilead Sciences

*
BGB-290: BeiGene

*
Eribulin: Eisai Inc.

*
Dapagliflozin: Novartis Pharmaceuticals

*
ADG106: Adagene Inc

*
Famitinib Malate: Jiangsu HengRui Medicine Co., Ltd

*
Talazoparib Tosylate: Pfizer

*
Letrozole: Novartis

*
CX-2009: CytomX Therapeutics

*
SM-88: Tyme, Inc

*
Neratinib: Puma Biotechnology, Inc.

*
G1T38: G1 Therapeutics, Inc.

*
Onapristone: Context Therapeutics Inc.

Discover more about therapies set to grab major HER2-Negative Metastatic Breast Cancer market share @ HER2-Negative Metastatic Breast Cancer Treatment Market [https://www.delveinsight.com/sample-request/her2-negative-metastatic-breast-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Scope of the HER2-Negative Metastatic Breast Cancer Market Report

*
Study Period: 2019-2032

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key HER2-Negative Metastatic Breast Cancer Companies: Genentech, Inc., AstraZeneca, Merck Sharp & Dohme LLC, Gilead Sciences, BeiGene, Eisai Inc., Novartis Pharmaceuticals, Adagene Inc, Jiangsu HengRui Medicine Co., Ltd, Pfizer, Novartis, CytomX Therapeutics, Tyme, Inc, Puma Biotechnology, Inc., G1 Therapeutics, Inc., Context Therapeutics Inc., and others

*
Key HER2-Negative Metastatic Breast Cancer Therapies: Paclitaxel, Doxorubicin, AZD9833, Pembrolizumab, TF2 - 68 Ga-IMP-288, BGB-290, Eribulin, Dapagliflozin, ADG106, Famitinib Malate, Talazoparib Tosylate, Letrozole, CX-2009, SM-88, Neratinib, G1T38, Onapristone, and others

*
HER2-Negative Metastatic Breast Cancer Therapeutic Assessment: HER2-Negative Metastatic Breast Cancer current marketed and HER2-Negative Metastatic Breast Cancer emerging therapies

*
HER2-Negative Metastatic Breast Cancer Market Dynamics: HER2-Negative Metastatic Breast Cancer market drivers and HER2-Negative Metastatic Breast Cancer market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
HER2-Negative Metastatic Breast Cancer Unmet Needs, KOL's views, Analyst's views, HER2-Negative Metastatic Breast Cancer Market Access and Reimbursement

To know more about HER2-Negative Metastatic Breast Cancer companies working in the treatment market, visit @ HER2-Negative Metastatic Breast Cancer Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/her2-negative-metastatic-breast-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. HER2-Negative Metastatic Breast Cancer Market Report Introduction

2. Executive Summary for HER2-Negative Metastatic Breast Cancer

3. SWOT analysis of HER2-Negative Metastatic Breast Cancer

4. HER2-Negative Metastatic Breast Cancer Patient Share (%) Overview at a Glance

5. HER2-Negative Metastatic Breast Cancer Market Overview at a Glance

6. HER2-Negative Metastatic Breast Cancer Disease Background and Overview

7. HER2-Negative Metastatic Breast Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of HER2-Negative Metastatic Breast Cancer

9. HER2-Negative Metastatic Breast Cancer Current Treatment and Medical Practices

10. HER2-Negative Metastatic Breast Cancer Unmet Needs

11. HER2-Negative Metastatic Breast Cancer Emerging Therapies

12. HER2-Negative Metastatic Breast Cancer Market Outlook

13. Country-Wise HER2-Negative Metastatic Breast Cancer Market Analysis (2019-2032)

14. HER2-Negative Metastatic Breast Cancer Market Access and Reimbursement of Therapies

15. HER2-Negative Metastatic Breast Cancer Market Drivers

16. HER2-Negative Metastatic Breast Cancer Market Barriers

17. HER2-Negative Metastatic Breast Cancer Appendix

18. HER2-Negative Metastatic Breast Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=her2negative-metastatic-breast-cancer-market-positioned-for-accelerated-development-through-2032-delveinsight-finds-genentech-astrazeneca-merck-sharp-dohme-llc-gilead-sciences-beigene-eisai]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.